Proactive Investors - Run By Investors For Investors

OptiBiotix Health unveils second distribution deal of the week for weight management product

It is teaming up with South Africa’s Formulation Creations, led by Gary Coulson, an industry expert with an “extensive network of customers and partners” in his local market
woman shows her waist has shrunk by holding open top of her jeans
The company's products help tackle obesity, high cholesterol and diabetes

OptiBiotix Health plc (LON:OPTI) has unveiled its second distribution agreement of the week for the company’s weight management product SlimBiome.

It has inked a deal with South Africa’s Formulation Creations, led by Gary Coulson, an industry expert with an “extensive network of customers and partners” in his local market.

Formulation already has partnerships with Gold Coast Ingredients, Real Stevia and Cambridge Commodities, OptiBiotix's UK distributor for SlimBiome.

“With such a wealth of local knowledge and technical expertise in the health and wellness sector, we are in a great position to offer the South African market bespoke concepts and weight management products to meet the demands of the local population,” said sales and marketing director Christina Wood.

News flow continues 

This is the AIM-listed group’s fourth piece of material news in ten days.

On Monday OptiBiotix said it had partnered with privately-owned functional foods business CTC Group, which will sell SlimBiome in the Philippines, Vietnam, Indonesia and Colombia.

The tie-up followed hard on the heels of a distribution agreement for its cholesterol product, CholBiome, and news that the group plans to spin out ProBiotix business.

OptiBiotix is a pioneer of the human microbiome, which is essentially the bacteria that inhabit the gut and skin.

It has found, for instance, small changes in the gut flora can affect the way the human body processes food.

Its products are focused on tackling obesity, diabetes and cholesterol.

View full OPTI profile View Profile

OptiBiotix Health PLC Timeline

Related Articles

Nemaura Medical Inc CEO Dr Faz Chowdhury
November 05 2018
The medtech company is eying explosive growth with sugarBEAT, on the cusp of launching in the UK, followed by the rest of Europe in 2018
An instrument made by Pressure BioSciences
June 26 2019
The company’s high-pressure technologies can help drug makers produce protein-based therapeutics, a market expected to touch $240 billion by 2023
PT exercises
December 19 2018
The Californian company is a bet on an industry that is in need of transformation

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use